Form 4: Precision BioSciences Director, Melinda Brown, Acquires Restricted Stock Units

Director Melinda Brown acquired 9,826 Restricted Stock Units (RSUs) in Precision BioSciences, Inc. on June 4, 2024, which will vest on the earlier of June 4, 2025, or the day before the next annual meeting.

Summary

• Melinda Brown, a director of Precision BioSciences, Inc. (DTIL), acquired 9,826 Restricted Stock Units (RSUs) on June 4, 2024.
• Each RSU represents the right to receive one share of Precision BioSciences' Common Stock or an equivalent cash amount.
• The RSUs will vest on the earlier of June 4, 2025, or the day immediately prior to the company's next annual meeting of stockholders, contingent upon continued service to the Issuer.
• Following the transaction, Ms. Brown directly owns 9,826 shares of Common Stock.

Sentiment

Score: 7

Explanation: The acquisition of RSUs by a director is generally viewed positively as it aligns their interests with the company's success. However, it's a routine transaction and doesn't necessarily indicate a major shift in the company's prospects.

Positives

• The acquisition of RSUs by a director signals confidence in the company's future performance.
• The vesting schedule incentivizes continued service and alignment with shareholder interests.

Future Outlook

The vesting of the RSUs is contingent upon continued service, aligning the director's interests with the long-term success of the company.

Industry Context

Form 4 filings are routine disclosures of insider transactions, providing transparency to investors regarding the actions of company directors and officers. This particular filing indicates an acquisition of RSUs, a common form of equity compensation.

Stakeholder Impact

• Shareholders may view the RSU acquisition positively as it aligns the director's interests with the company's performance.
• Employees may see this as a positive sign of management's commitment to the company.

Key Dates